Anti-vascular endothelial growth factor for diabetic macular oedema

Virgili, Gianni; Parravano, Mariacristina; Menchini, Francesca; Evans, Jennifer R

doi:10.1002/14651858.cd007419.pub4

Cited by 166 publications

(128 citation statements)

References 111 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…grid laser photocoagulation, or no treatment when laser is not an option [15]. The quality and quantity of the evidence was larger for ranibizumab, but there was little power to investigate drug differences [16].…”

Section: Discussionmentioning

confidence: 99%

Bevacizumab in diabetic macular edema. A retrospective analysis of the efficacy of treatment in a group of 100 patients

2017

View full text Add to dashboard Cite

introduCtion. The aim of the study was to retrospectively evaluate the efficacy of intravitreal injections of bevacizumab in a large group of diabetic macular edema (DME) patients. MateriaLs and Methods. One hundred patients (125 eyes) suffering from diabetes type 1 or 2 and DME were treated with two or three monthly 1.25-mg intravitreal injections of bevacizumab. resuLts. The mean (SD) best correct visual acuity (BCVA) before treatment was 63.8 (± 26.2) letters. At months 1, 2, and 3 the mean change (SE) in BCVA from baseline was +4.4 (± 0.49), +4.9 (0.38), and +3.1 (± 0.39) letters, respectively. The mean macular retinal thickness dropped from 457 (± 183) microns to 308 (± 122) microns after three months. The improvement of retinal morphology in optical coherence tomography was evident: a decrease in the number of intraretinal cysts and a generalised shrinkage of retinal macular edema. There were no serious adverse effects of the treatment. ConCLusion. The majority of patients with DME showed an improvement in visual acuity, particularly after the first injection of bevacizumab. Bevacizumab therapy is an interesting alternative to DME treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Bevacizumab in diabetic macular edema. A retrospective analysis of the efficacy of treatment in a group of 100 patients

2017

View full text Add to dashboard Cite

show abstract

“…86 This was in contrast to an older Cochrane review published in 2014 that found no difference in systemic adverse events in those treated with anti-VEGF agents on an as-needed basis versus those who had not. 87 These disparate results, we postulate, could be due to more stringent inclusion criteria of the first study requiring imposed monthly injections for two years, while the latter included studies with far fewer treatments. Thus, there are safety concerns in premature infants but to what effect remains unseen.…”

Section: Anti-vascular Endothelial Growth Factormentioning

confidence: 98%

The Role of Anti-vascular Endothelial Growth Factor Agents in the Management of Retinopathy of Prematurity

Conrady¹,

Hartnett²

2017

US Ophthalmic Review

View full text Add to dashboard Cite

show abstract

“…These authors 17 investigated the effects of preserving or improving vision, acceptance, security and quality of life with this drug. The authors concluded that there was high-quality evidence favoring use of antiangiogenic drugs, compared with photocoagulation, over a period of one to two years.…”

Section: Anti-vascular Endothelial Growth Factor For Diabetic Macularmentioning

confidence: 99%

What do Cochrane systematic reviews say about diabetic retinopathy?

et al. 2017

View full text Add to dashboard Cite

CONTEXT AND OBJECTIVE: Diabetic retinopathy is a disease caused by increased permeability of retinal vessels. Its incidence and prevalence have been increasing due to urbanization, greater life expectancy and the habits of modern life. Its onset is insidious and it may lead to blindness in 75% of individuals who have been diabetic for more than 20 years. The aim here was to evaluate the evidence from Cochrane systematic reviews on interventions relating to diabetic retinopathy. DESIGN AND SETTING: Review of systematic reviews, conducted at Cochrane Brazil. METHODS:We included Cochrane systematic reviews on interventions relating to diabetic retinopathy. Two researchers evaluated the inclusion criteria, summarized the reviews and presented the results narratively. RESULTS: Ten reviews met the inclusion criteria. They showed some evidence of benefits from: (a) photocoagulation for diabetic retinopathy; (b) strict glucose and pressure control for postponing the onset of retinopathy; (c) antiangiogenic drugs for macular edema (high-quality evidence); (d) anti-vascular endothelial growth factor agents for proliferative diabetic retinopathy (very low to low-quality evidence); and (e) intravitreal injection or surgical implantation for treating persistent or refractory macular edema. However, blood pressure control seems to have no benefit after the onset of retinopathy. CONCLUSION: Only a few options are likely to be effective for treating diabetic retinopathy. These include photocoagulation and anti-vascular endothelial growth factor agents. Strict glucose and pressure control seem to postpone the onset of retinopathy. For macular edema, antiangiogenic drugs, intravitreal injection and surgical implantation seem to have some benefit. RESUMO CONTEXTO:A retinopatia diabética é uma doença causada pelo aumento da permeabilidade dos vasos da retina. Sua incidência e prevalência vêm aumentando devido à urbanização, maior expectativa de vida e hábitos de vida modernos. Seu início é insidioso e pode levar à cegueira em 75% dos pacientes diabéti-cos com mais de 20 anos de doença. O objetivo foi avaliar a evidência das revisões sistemáticas Cochrane sobre intervenções para retinopatia diabética.

show abstract

Anti-vascular endothelial growth factor for diabetic macular oedema

Cited by 166 publications

References 111 publications

Bevacizumab in diabetic macular edema. A retrospective analysis of the efficacy of treatment in a group of 100 patients

Bevacizumab in diabetic macular edema. A retrospective analysis of the efficacy of treatment in a group of 100 patients

The Role of Anti-vascular Endothelial Growth Factor Agents in the Management of Retinopathy of Prematurity

What do Cochrane systematic reviews say about diabetic retinopathy?

Contact Info

Product

Resources

About